PDS Biotechnology (NASDAQ:PDSB) saw its stock price rise on Thursday following the biotech’s announcement that an independent panel has recommended Keytruda and Merck’s (NYSE:MRK) anti-PD-1 treatment, Keytruda, be used in the VERSATILE-002 study for main asset PDS0101.
Based on safety results from the investigational PDS0101 and Keytruda combination study for HPV16-positive head and neck cancer, the independent Data Monitoring Committee (DMC) made its decision.
The business claims that the DMC analysis of 43 patients showed no drug discontinuations due to toxicity or treatment-related adverse events of Grade 3 or above.
PDS Biotech (NASDAQ:PDSB) stated in May that the U.K. regulators had approved its proposal to carry out the VERSATILE-002 trial there.
What Does PDS Biotechnology Do?
PDS Biotech is an immunotherapy firm in the clinical stages of development. The company’s unique Versamune® and InfectimuneTM T cell activating technology platforms serve as the foundation for a growing pipeline of immunotherapies for cancer and infectious diseases.
By producing a significant number of high-quality, convenient, and polyfunctional tumor-specific CD4+ helper and CD8+ killer T cells in vivo, the company believes its Versamune®-based medicines have shown the ability to overcome the drawbacks of conventional immunotherapy.
Versamune® and disease-specific antigens are the foundation of several medicines created by PDS Biotech to help the immune system become more adept at identifying and attacking sick cells.
The company keeps moving forward with its pipeline of preclinical and clinical prospects to treat a variety of cancers, including those linked to HPV16 (ovarian, breast, colon, lung, prostate, and head and neck cancers).
PDS Biotech’s InfectimuneTM-based vaccines have shown the ability to elicit significant T cell responses, including long-lasting memory T cell responses, in addition to robust and long-lasting neutralizing antibody responses.
Company Officials Plan Fireside Chat Next Week
PDS Biotechnology Corporation (NASDAQ: PDSB) recently announced that its management would participate in a fireside chat and one-on-one meetings at the BTIG Biotechnology Conference, a hybrid event taking place August 8–9, 2022.
Featured Image: Megapixl © Kentoh
